| Literature DB >> 29081998 |
Aduragbemi Banke-Thomas1, Barbara Madaj1, Shubha Kumar2, Charles Ameh1, Nynke van den Broek1.
Abstract
Responding to increasing demands to demonstrate value-for-money (VfM) for maternal and newborn health interventions, and in the absence of VfM analysis in peer-reviewed literature, this paper reviews VfM components and methods, critiques their applicability, strengths and weakness and proposes how VfM assessments can be improved. VfM comprises four components: economy, efficiency, effectiveness and cost-effectiveness. Both 'economy' and 'efficiency' can be assessed with detailed cost analysis utilising costs obtained from programme accounting data or generic cost databases. Before-and-after studies, case-control studies or randomised controlled trials can be used to assess 'effectiveness'. To assess 'cost-effectiveness', cost-effectiveness analysis (CEA), cost-utility analysis (CUA), cost-benefit analysis (CBA) or social return on investment (SROI) analysis are applicable. Generally, costs can be obtained from programme accounting data or existing generic cost databases. As such 'economy' and 'efficiency' are relatively easy to assess. However, 'effectiveness' and 'cost-effectiveness' which require establishment of the counterfactual are more difficult to ascertain. Either a combination of CEA or CUA with tools for assessing other VfM components, or the independent use of CBA or SROI are alternative approaches proposed to strengthen VfM assessments. Cross-cutting themes such as equity, sustainability, scalability and cultural acceptability should also be assessed, as they provide critical contextual information for interpreting VfM assessments. To select an assessment approach, consideration should be given to the purpose, data availability, stakeholders requiring the findings and perspectives of programme beneficiaries. Implementers and researchers should work together to improve the quality of assessments. Standardisation around definitions, methodology and effectiveness measures to be assessed would help.Entities:
Keywords: Health Economics; Health Services Research; Health Systems Evaluation; Obstetrics
Year: 2017 PMID: 29081998 PMCID: PMC5656121 DOI: 10.1136/bmjgh-2017-000310
Source DB: PubMed Journal: BMJ Glob Health ISSN: 2059-7908
Figure 1Overseas development assistance (ODA) for maternal and newborn health, 2003–2013.
Figure 2‘Economy, effectiveness and efficiency (3Es) and cost-effectiveness (CE)’ framework for value-for-money.
Comparison of methods for assessing cost-effectiveness
| Cost-effectiveness analysis (CEA) | Cost-utility analysis subtype of CEA | Cost-benefit analysis (CBA) | Social return on investment (SROI) |
| Main objective | |||
| Compare costs and outcomes of alternatives within the same domain | Compare costs and outcome of alternatives within the same domain | Assess worthwhileness of the investment made in implementing an intervention | Assess worthwhileness of the investment made in implementing an intervention, from the perspective of stakeholders |
| Accounting for costs | |||
| Monetary value. Multiple sources can be explored, including direct and indirect costs as well as different perspectives | Monetary value | Monetary value | Monetary value |
| Accounting for benefits | |||
| Benefits referred to as ‘effectiveness’, which is reported as ‘natural units’ such as life years gained. | Benefits referred to as ‘utility’, which is reported as quality adjusted life years gained/disability adjusted life years averted/healthy life years gained | Benefits include both health and non-health outcomes, which are reported as monetary value or welfare benefit. Benefits that are difficult to monetise are listed | Benefits include both health and non-health outcomes, including social, economic and environmental outcomes. Both positive and negative effects are accounted for. Benefits are reported as monetary value or welfare benefit, using financial proxies to show monetary value of benefits that cannot be easily monetised. |
| Level of application | |||
| Single intervention level | Single intervention level | Single or multiple intervention(s), project or programme level | Single or multiple intervention(s), project, programme, policy or organisation level |
| Time line of analysis | |||
| Retrospective or prospective | Retrospective or prospective | Retrospective or prospective | Retrospective (evaluative type) or prospective (forecast type) |
| Discounting of future value | |||
| Applicable | Applicable | Applicable | Applicable |
| Stakeholder engagement | |||
| Not required | Not required | Not required | Multiple stakeholders required |
| Theory of change | |||
| Not required for conduct | Not required for conduct | Not required for conduct | Required for conduct |
| Main output of analysis | |||
| Incremental cost-effectiveness ratio (ICER). Sensitivity analysis is applicable | ICER. Sensitivity analysis is applicable | Benefit-cost ratio (BCR), economic internal rate of return, net present value (NPV), break-even point. Sensitivity analysis is applicable | SROI ratio, NPV, payback period. |
| Interpretation of main output of analysis | |||
| Intervention with higher cost-effectiveness ratio is better | Intervention with higher cost-effectiveness ratio is better | BCR >1 is worthwhile investment | SROI ratio >1 is worthwhile investment |
| Relevance | |||
| Priority setting and resource allocation | Priority setting and resource allocation | Priority setting and resource allocation | Priority setting, resource allocation, stakeholder relationship building, accountability framework and management tool |